Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sapio Sciences Announces Exemplar LIMS for Clinical and Research NGS Labs

Published: Tuesday, February 25, 2014
Last Updated: Tuesday, February 25, 2014
Bookmark and Share
Purpose-built system handles the sample tracking and processing needs of clinical or research laboratories

Sapio Sciences has announced Exemplar LIMS for clinical and research NGS labs.   Exemplar NGS LIMS is a system built to handle the sample tracking and processing needs of clinical or research laboratories. Exemplar provides complete tracking of samples through the NGS pipeline from request through sample processing and results delivery. It provides automation integration as needed, along with preconfigured workflows, management level dashboards, full consumables management and support for regulatory compliance such as CLIA.

The dynamic nature of the NGS lab requires a LIMS that can adapt quickly to changing protocols and platforms. Exemplar is the most configurable LIMS at all levels, meaning that no matter what technology you introduce into your lab or what your requirements are, you can be confident that Exemplar can meet your needs.

When evaluating a LIMS, labs should choose a system that:

Is fully web based for complete end user usage and configuration and is usable on tablet computers.
Tracks volumes of samples through the pipeline
Has pre-built, CLIA standard, NGS workflows
Fully tracks aliquot and derivative lineage
Tracks samples and workflows throughout the pipeline.
Collects quality control data and integrates with all leading QC genomics instruments.
Can fully track consumables including amount remaining in inventory and expiration dates.
Is highly configurable to easily alter existing workflows and when creating new ones.
Includes graphical dashboards of lab activity
Is highly scalable to handle anticipated concurrent users and sample volumes for many years
Can support any additional lab process outside the NGS arena
This extent of this list is daunting for a new MDx company to consider as a thorough implementation of these features could require 4 or more software solutions and years of work. New labs also need to get CLIA certification and may also need to operate under GLP and/or be a validated lab per FDA Part 11 specifications.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos